Radiosurgery for Central Neurocytoma.

Q2 Medicine

Progress in neurological surgery Pub Date : 2019-01-01 Epub Date: 2019-05-16 DOI:10.1159/000493069

Aya Nakamura, Hideyuki Kano, Ajay Niranjan, L Dade Lunsford

引用次数: 8

Abstract

The classification of central neurocytoma (CN) by the WHO was upgraded to grade 2 in 1993 as it was recognized that at least some of these tumors can exhibit more aggressive behavior. Currently, as of 2016, CN is classified as WHO grade 2. Indeed, some atypical variants have been reported and residual postsurgical tumor is believed to have the potential for malignant transformation. Although gross total resection is usually curative for CN (5-year survival rate 99%), it is achieved in nearly 30-50% of cases due to its central location. Adjuvant treatments should be deliberately considered for the optimal management of CN. Recently, stereotactic radiosurgery is increasingly proposed as an adjuvant treatment for CN.

查看原文本刊更多论文

中枢神经细胞瘤的放射外科治疗。

世界卫生组织在1993年将中枢神经细胞瘤(CN)的分类提升到2级，因为人们认识到至少其中一些肿瘤可以表现出更具侵略性的行为。目前，截至2016年，CN被WHO列为2级。事实上，一些非典型的变异已经被报道，残留的术后肿瘤被认为有恶性转化的潜力。虽然总切除通常是CN的治愈方法(5年生存率99%)，但由于其中心位置，近30-50%的病例可以实现。辅助治疗是CN的最佳治疗方法。最近，立体定向放射外科越来越多地被建议作为CN的辅助治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Progress in neurological surgery Medicine-Surgery

自引率

0.00%

发文量

期刊介绍： Published since 1966, this series has become universally recognized as the most significant group of books serving neurological surgeons. Volumes feature contributions from distinguished international surgeons, who brilliantly review the literature from the perspective of their own personal experience. The result is a series of works providing critical distillations of developments of central importance to the theory and practice of neurological surgery.